Acura, King Receive FDA’ Complete Response Letter For Acurox
Acura and King Pharmaceuticals have announced that FDA has issued a Complete Response Letter regarding the New Drug Application (NDA) for Acurox Tablets CII. Its an immediate release
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).